## James R Seibold

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/89664/publications.pdf

Version: 2024-02-01

8 papers

4,272 citations

1306789 7 h-index 7 g-index

8 all docs 8 docs citations

8 times ranked 5373 citing authors

#	Article	IF	CITATIONS
1	Response to:  Correspondence on  Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'' by Bredemeier. Annals of the Rheumatic Diseases, 2022, 81, e251-e251.	0.5	O
2	Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the ⟨scp⟩INBUILD⟨/scp⟩ Trial. Arthritis and Rheumatology, 2022, 74, 1039-1047.	2.9	44
3	Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. Autoimmunity Reviews, 2021, 20, 102978.	2.5	17
4	Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Annals of the Rheumatic Diseases, 2020, 79, 1478-1484.	0.5	46
5	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. Journal of Clinical Epidemiology, 2014, 67, 706-714.	2.4	52
6	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
7	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2013, 72, 1747-1755.	0.5	1,705
8	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	1.5	49